- Fecal Incontinence
This enduring activity has been designed to meet the educational needs of gastroenterologists, primary care providers, nurse practitioners, physician assistants, allied healthcare professionals, clinical pharmacists, and managed care decision makers.
Upon completion of this activity, participants should be better able to:
Discuss the evolution of therapeutic goals and clinical endpoints for IBD treatment
Design and implement evidence based treatment plans for patients with IBD
Describe the similarities, differences, and safety profiles of the novel biologic therapies in development
Describe the goals of management and methods for following the efficacy of various treatment strategies for FGIDs
Design a treatment plan that effectively incorporates current understanding of the pathophysiology of FGIDs, guideline recommendations, and the most recent evidence from the literature
Apply evidence-based strategies to tailor initial and ongoing treatment by stratification of patients by disease subtype, individual symptoms, and previous medications
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Gi Health Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: February 12, 2015
Expiration Date: February 12, 2016
*This program has expired. CME credit is no longer available.
NOTE: All webcasts must be viewed in their entirety in order to receive full credit.
Disclosure of Conflicts of Interest
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education (ACHS), consults for Pfizer, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and The Gi Health Foundation has no relationships to disclose.
Faculty Disclosure Statements
Stephen Hanauer is a Consultant for AbbVie, Actavis, Ferring, Janssen Biotech, Inc., Pfizer, Prometheus Laboratories, Salix, sanofi-aventis, Shire, Takeda Pharmaceuticals International Inc., UCB. He has performed Clinical Research for AbbVie, Janssen Biotech, Inc., Pfizer, Prometheus Laboratories, sanofi-aventis, Takeda Pharmaceuticals International Inc., UCB and is a speaker for AbbVie, Janssen Biotech Inc., Takeda Pharmaceuticals International Inc.
Philip Schoenfeld is a Consultant or member of a speaker bureau for Salix Pharmaceuticals, Ironwood Pharmaceuticals, and Forest Laboratories. He is a member of an advisory board for Salix Pharmaceuticals, Ironwood Pharmaceuticals, Forest Laboratories and Synthetic Biologics. He also has had Editorial Board Involvement as Associate Editor, Gastroenteroloy; Editorial Board, Gastroenterology & Hepatology. He is also a Partner in MD-Evidence, LLC.
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Supported by an educational grant from AbbVie, Actavis, AstraZeneca Pharmaceuticals LP, Janssen Biotech, Inc., administered by Janssen Services, LLC, and UCB, Inc.